Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings

Immune checkpoint inhibitors (ICIs) are rapidly being incorporated as treatment option either alone or in combination with chemotherapy in most of the solid tumors. Since there is very limited data of ICI in patients with poor performance status (PS) from the real world settings, we performed a retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Akhil, Noronha, Vanita, Patil, Vijay M., Menon, Nandini, Joshi, Amit, Abraham, George, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021372/
https://www.ncbi.nlm.nih.gov/pubmed/33787593
http://dx.doi.org/10.1097/MD.0000000000025115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021372/
https://www.ncbi.nlm.nih.gov/pubmed/33787593
http://dx.doi.org/10.1097/MD.0000000000025115

Ejemplares similares